The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases

References

• Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER–mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131(3):596–610.
   PubMed Web of Science ®Google Scholar
• Martin WR, Eades CG, Thompson JA, et al. The effects of morphine- and nalmorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197(3):517–532.
   PubMed Web of Science ®Google Scholar
• Su TP. Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther. 1982;223(2):284–290.
   PubMed Web of Science ®Google Scholar
• Vaupel DB. Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog. Eur J Pharmacol. 1983;92(3–4):269–274.
   PubMed Web of Science ®Google Scholar
• Wong EH, Knight AR, Woodruff GN. [3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem. 1988;50(1):274–281.
   Web of Science ®Google Scholar
• Gundlach AL, Largent BL, Snyder SH. Phencyclidine and sigma opiate receptors in brain: biochemical and autoradiographical differentiation. Eur J Pharmacol. 1985;113(3):465–466.
   PubMed Web of Science ®Google Scholar
• Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci. 1992;13(3):85–86.
   PubMed Web of Science ®Google Scholar
• Bowen WD, Hellewell SB, McGarry KA. Evidence for a multi-site model of the rat brain sigma receptor. Eur J Pharmacol. 1989;163(2–3):309–318.
   Web of Science ®Google Scholar
• Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A. 1996;93(15):8072–8077.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Intracellular dynamics of sigma-1 receptors (sigma-1 binding sites) in NG108–15 cells. J Pharmacol Exp Ther. 2003;306(2):726–733.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Sigma-1 receptors (sigma-1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther. 2003;306(2):718–725.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future. 2009;34(29):137–146.
   Google Scholar
• Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85–94.
   PubMed Web of Science ®Google Scholar
• Weissman AD, Casanova MF, Kleinman JE, et al. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry. 1991;29(1):41 –54.
   Web of Science ®Google Scholar
• Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic cerebral cortices. Neurochem Res. 1992;17(10):983–990.
   Web of Science ®Google Scholar
• Tam SW, Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci U S A. 1984;81(17):5618–5621.
   Web of Science ®Google Scholar
• Shimazu S, Katsuki H, Takenaka C, et al. Sigma receptor ligands attenuate N-methyl-D-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice cultures. Eur J Pharmacol. 2000;388(2):139–146.
   Web of Science ®Google Scholar
• Urani A, Romieu P, Portales-Casamar E, et al. The antidepressant-like effect induced by the sigma-1 (sigma-1) receptor agonist igmesine involves modulation of intracellular calcium mobilization. Psychopharmacology (Berl). 2002;163(1):26–35.
   PubMed Web of Science ®Google Scholar
• Moison D, De Deurwaerdere P, Cagnotto A, et al. Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo. Neuropharmacology. 2003;45(7):945–953.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–1308.
   PubMed Web of Science ®Google Scholar
• Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52(12):998–1007.
   PubMed Web of Science ®Google Scholar
• Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158(9):1367–1377.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the NMDA receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003;60(6):572–576.
   Web of Science ®Google Scholar
• Hashimoto K, Okamura N, Shimizu E, et al. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem CNSAgents. 2004;4(2):147–154.
   Google Scholar
• Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev. 2005;1(2):151–163.
   Google Scholar
• Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci. 2006;4(1):3–10.
   Google Scholar
• Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs. 2004;18(5):269–284.
   PubMed Web of Science ®Google Scholar
• Modell S, Naber D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry. 1996;29(2):63–66.
   Web of Science ®Google Scholar
• Huber MT, Gotthardt U, Schreiber W, et al. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry. 1999;32(2):68–72.
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321–330.
   PubMed Web of Science ®Google Scholar
• Ishima T, Fujita Y, Kohno M, et al. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J. 2009;2(5):7–11.
   Google Scholar
• Kunitachi S, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res. 2009;1279:189–196.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. 2007;32(3):514–551.
   Web of Science ®Google Scholar
• Okuyama S, Nakazato A. NE-100: a novel sigma receptor antagonist. CNS Drug Rev. 1996;2(2):226–237.
   Google Scholar
• Silver H, Barash I, Aharon N, et al. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol. 2000;15(5):257–261.
   Web of Science ®Google Scholar
• Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev. 2001;7(3):283–304.
   PubMedGoogle Scholar
• Iyo M, Shirayama Y, Watanabe H, et al. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):1072–1073.
   Web of Science ®Google Scholar
• Shirayama Y, Takahashi K, Nishikawa T. Uncompetitive inhibition of [3H]1,3-di-O-tolyl-guanidine-defined sigma binding sites by desipramine, propranolol and alprenolol in rat brain. Eur J Pharmacol. 1997;331(2–3):319–323.
   Web of Science ®Google Scholar
• Ishiguro H, Ohtsuki T, Toru M, et al. Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia. Neurosci Lett. 1998;257(1):45–48.
   Web of Science ®Google Scholar
• Ohmori O, Shinkai T, Suzuki T, et al. Polymorphisms of the sigma-1 receptor gene in schizophrenia: An association study. Am J Med Genet. 2000;96(1):118–122.
   PubMed Web of Science ®Google Scholar
• Satoh F, Miyatake R, Furukawa A, et al. Lack of association between sigma receptor gene variants and schizophrenia. Psychiatry Clin Neurosci. 2004;58(4):359–363.
   PubMed Web of Science ®Google Scholar
• Takizawa R, Hashimoto K, Tochigi M, et al. Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia. Prog NeuropsychopharmacolBiol Psychiatry. 2009;33(3):491–498.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report: 2004: Changing History, Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. Geneva, Switzerland: World Health Organization; 2004.
   Google Scholar
• Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry. 2005;62(6):617–627.
   PubMed Web of Science ®Google Scholar
• Matsuno K, Kobayashi T, Tanaka MK, et al. Sigma-1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol. 1996;312(3):267–271.
   PubMed Web of Science ®Google Scholar
• Roman FJ, Pascaud X, Martin B, et al. JO 1784, a potent and selective ligand for rat and mouse brain sigma-sites. J Pharm Pharmacol. 1990;42(6):439–440.
   PubMed Web of Science ®Google Scholar
• Matsuno K, Nakazawa M, Okamoto K, et al. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol. 1996;306(1–3):271–279.
   Web of Science ®Google Scholar
• Urani A, Roman FJ, Phan VL, et al. The antidepressant-like effect induced by sigma-1 receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther. 2001;298(3):1269–1279.
   PubMed Web of Science ®Google Scholar
• Tottori K, Miwa T, Uwahodo Y, et al. Antidepressant-like responses to the combined sigma and 5-HT^ receptor agonist OPC-14523. Neuropharmacology. 2001;41(8):976–988.
   Web of Science ®Google Scholar
• Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci. 2005;97(3):317–336.
   Web of Science ®Google Scholar
• Sabino V Cottone P, Parylak SL, et al. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res. 2009;198(2):472–476.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Ishima T, Iyo M, et al. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008;3(7):e25358.
   Web of Science ®Google Scholar
• Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology. 1998;23(8):963–987.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Kaur G, Kulkarni SK. Sigma (sigma-1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. J Pharmacol Exp Ther. 2001;298(3):1269–1279.
   Google Scholar
• Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl). 2004;174(3):301–319.
   PubMed Web of Science ®Google Scholar
• Skuza G, Wedzony K. Behavioral pharmacology of sigma-ligands. Pharmacopsychiatry. 2004;37(Suppl 3):S183–S188.
   Google Scholar
• Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006;12(30):3857–3876.
   Web of Science ®Google Scholar
• Cobos EJ, Entrena JM, Nieto FR, et al. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol. 2008;6(4):344–366.
   PubMed Web of Science ®Google Scholar
• Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther. 2009;124(2):195–206.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry. 2003;64(Suppl 1):19–23.
   Google Scholar
• Vythilingam M, Chen J, Bremner JD, et al. Psychotic depression and mortality. Am J Psychiatry. 2003;160(3):574–576.
   Web of Science ®Google Scholar
• Gatti F, Bellini L, Gasperini M, et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry. 1996;153(3):414–416.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs. J Clin Psychiatry. 1999;60(5):326–335.
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M, et al. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. J Clin Psychopharmacol. 1998;18(6):441–446.
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M, et al. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry. 1996;153(12):1631–1633.
   PubMed Web of Science ®Google Scholar
• Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307(1):117–119.
   Web of Science ®Google Scholar
• Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem. 2009;9(3):197–204.
   PubMedGoogle Scholar
• Shirayama Y, Hashimoto K. A case of psychotic depression treated with fluvoxamine monotherapy. Clin Psychopharmacol Neurosci. In press 2010.
   Google Scholar
• Stahl SM. Antidepressant treatment of psychotic major depression: Potential role of the sigma receptor. CNS Spectr. 2005 ;10(4):319–323.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Understanding the role of sigma-1 receptors in Psychotic depression. Psychiatr Times. 2005;22(11):54–63.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Publishing; 2000.
   Google Scholar
• Dell’Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005;6(15):2727–2740.
   PubMed Web of Science ®Google Scholar
• Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsy-chiatrDis Treat. 2005;1(4):289–299.
   PubMedGoogle Scholar
• Ordacgi L, Mendlowicz MV Fontenelle LF Management of obsessive-compulsive disorder with fluvoxamine extended release. Neuropsychiatr Dis Treat. 2009;5:301–308.
   Web of Science ®Google Scholar
• Egashira N, Harada S, Okuno R, et al. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. Eur J Pharmacol. 2007;563(1–3):149–154.
   Web of Science ®Google Scholar
• Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165(5):621–630.
   PubMed Web of Science ®Google Scholar
• Clark DA. Cognitive-Behavioral Therapy for OCD. New York, NY: Guilford; 2004.
   Google Scholar
• Cottraux J, Mollard E, Bouvard M, et al. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res. 1993;49(1):63–75.
   Web of Science ®Google Scholar
• Hohagen F, Winkelmann G, Rasche-Rüchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl. 1998;(35):71–78.
   Google Scholar
• Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351(1):56–67.
   PubMed Web of Science ®Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.
   PubMed Web of Science ®Google Scholar
• Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25–35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol. 2006;149(8):998–1012.
   PubMed Web of Science ®Google Scholar
• Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1656–1659.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Sakata M, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol. 2009;12(8):1127–1131.
   PubMed Web of Science ®Google Scholar
• Jansen KL, Faull RL, Storey P, et al. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer’s disease correlates with CA1 pyramidal cell loss. Brain Res. 1993;623(2):299–302.
   Web of Science ®Google Scholar
• Mishina M, Ohyama M, Ishii K, et al. Low density of sigma1 receptors in early Alzheimer’s disease. Ann Nucl Med. 2008;22(3):151–156.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Ishiwata K, Tajima H, et al. In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma-1 receptors. Nucl Med Biol. 2000;27(3):255–261.
   Web of Science ®Google Scholar
• Kawamura K, Elsinga PH, Kobayashi T, et al. Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]- 4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol. 2003;30(3):273–284.
   Web of Science ®Google Scholar
• Ishiwata K, Ishii K, Kimura Y, et al. Successive positron emission tomography measurement of cerebral blood flow and neuroreceptors in the human brain: an 11C-SA4503 study. Ann Nucl Med. 2008;22(5):411–416.
   Web of Science ®Google Scholar
• Ishiwata K, Oda K, Sakata M, et al. A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma-1 and dopamine D2-like receptors. Ann Nucl Med. 2006;20(8):569–573.
   Web of Science ®Google Scholar
• Ishikawa M, Ishiwata K, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvox-amine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007;62(8):878–883.
   PubMed Web of Science ®Google Scholar